Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link LY3437943, a novel triple glucagon, GIP, and GLP 1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept ScienceDirect Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Structural Biophysics Guided Computational Design of Semaglutide Analogues to Enhance GLP 1R Activation Article (Preprint v1) by Wei Li Qeios GLP1 Receptor Agonist Mechanisms GLP1RAs mimic the effects of Human Glucagon Like Peptide1 (GLP1), 'fooling your body' into thinking you ingested more than you actually have, causing earlier onset fullness & eventual